Phase I study of the novel and potent HCV NS5A inhibitor GS-5885 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2010
At a glance
- Drugs Ledipasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2010 Preliminary results were presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases.
- 31 Oct 2010 New trial record